Phase 3 trial of the antiangiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy.

Trial Profile

Phase 3 trial of the antiangiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs Thalidomide (Primary) ; Carboplatin; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Biomarker; Therapeutic Use
  • Acronyms NVALT-5
  • Most Recent Events

    • 04 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top